Format

Send to

Choose Destination
Ann Oncol. 2012 Mar;23(3):736-42. doi: 10.1093/annonc/mdr157. Epub 2011 May 20.

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

Author information

1
Department of Hematology, Postgraduate Program in Internal Medicine, School of Medicine, Federal University of Rio de Janeiro, Brazil.

Abstract

BACKGROUND:

A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL).

PATIENTS AND METHODS:

The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides.

RESULTS:

There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS.

CONCLUSION:

CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.

PMID:
21602260
PMCID:
PMC3331732
DOI:
10.1093/annonc/mdr157
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center